Early Subtypes and Progressions of Progressive Supranuclear Palsy: A Data-Driven Brain Bank Study.

Abstract

Background: Progressive supranuclear palsy (PSP) is typically characterized by vertical supranuclear gaze palsy and early falls, referred to as Richardson's syndrome (PSP-RS). Other presentations include postural instability (PSP-PI), parkinsonism (PSP-P), speech/language impairment (PSP-SL), frontal presentation (PSP-F), ocular motor dysfunction (PSP-OM), and corticobasal syndrome (PSP-CBS). Differences across the early presentations and in their subsequent progression have yet to be elucidated.

Objective: This study aimed to characterize early PSP subtypes and their subsequent progressions using a large postmortem dataset.

Methods: An automated pipeline incorporating fine-tuned ChatGPT models was developed. The pipeline collected 195 clinical features with onset information from autopsy-confirmed PSP cases without significant neurodegenerative co-pathologies.

Results: A structured clinicopathologic dataset from 588 patients was analyzed. After distilling results with unsupervised clustering, a decision tree model was developed. With five clinical manifestations: frontal presentation, PI, OM, SL, and parkinsonism, this mutually exclusive algorithm identified seven subtypes: PSP-PF (postural and frontal dysfunction), PSP-RS, PSP-PI, PSP-P, PSP-SL, PSP-F, and PSP-OM. PSP-PF, defined by PI and frontal presentation, showed rapid progression, the shortest median disease duration (six years), and high tau burden in cortical and subcortical regions. In PSP-F, frontal presentation preceded other symptoms by four years, and the disease duration was the second longest (nine years) after PSP-P (10 years). PSP-CBS was not identified as an independent subtype.

Conclusions: This data-driven study identified a novel, aggressive PSP phenotype characterized by early postural and frontal dysfunction. Early subtyping utilizing the decision tree would help clinicians estimate progression and facilitate early patient recruitment for clinical trials.